无铂间期(PFI)与维持治疗在复发性卵巢癌中对生存的影响:法国ESME卵巢数据库真实世界分析
基于法国ESME卵巢数据库的回顾性研究纳入5558例一线铂类化疗后首次复发的上皮性卵巢癌患者,分析无铂间期对无进展生存和总生存的影响及复发时治疗的作用。结果显示无铂间期延长与二线和三线PFS及OS成比例升高,铂类化疗优于单药化疗,二线使用PARP抑制剂似乎降低三线结局。
要点
- 无铂间期延长与二线、三线PFS和OS成比例升高。
- 即使PFI<6个月,铂类化疗仍优于单药化疗(PFSn2校正HR=0.48,95%CI 0.43-0.53)。
- 二线使用PARP抑制剂似乎降低三线结局,需前瞻性试验研究。
核心结论
- PFI仍是重要预后因素,但不应再作为复发性EOC尤其是HGSC复发时治疗选择的唯一考虑。
- 既往PARP抑制剂维持治疗对后续铂类化疗的潜在影响需在前瞻性试验中研究。
研究设计与样本
- 回顾性研究,使用法国ESME卵巢数据库,纳入一线铂类化疗后首次复发的上皮性卵巢癌患者。
- 共纳入5558例患者,治疗时间为2010年至2019年,中位年龄65岁(IQR 57-71)。
- 采用多因素Cox回归分析预后因素对生存的影响,结果以风险比表示,并根据患者和肿瘤特征进行校正,包括高级别浆液性癌亚组分析。
主要发现
- 中位二线和三线PFS及OS随PFI延长而成比例升高。
- 影响PFS和OS的其他因素包括BRCA突变、FIGO分期、化疗和维持治疗方案以及PS。
- 即使PFI<6个月,铂类化疗仍比单药化疗更有效(PFSn2:校正HR=0.48,95%CI 0.43-0.53;OSn2:HR=0.51,95%CI 0.46-0.57)。
- 二线使用PARP抑制剂似乎降低三线结局。
- 上述结果在高级别浆液性癌亚组中一致。
临床怎么用
- PFI仍是重要预后因素,但不应再作为复发性EOC尤其是HGSC复发时治疗选择的唯一考虑。
- 作者认为既往PARP抑制剂维持治疗对后续铂类化疗的潜在影响需在前瞻性试验中研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Approximately 70 % of patients with epithelial ovarian cancer (EOC) will relapse. Beyond the platinum-free interval (PFI), predictive factors for efficacy of subsequent therapies are poorly understood. We evaluated the impact of the PFI on progression-free survival (PFS), overall survival (OS) and the role of therapies used at relapse. METHODS: This retrospective study using the French ESME Ovarian Database included patients with first relapse of EOC after front-line platinum-based chemotherapy (PBCT). The impact of prognostic factors on survival was analyzed using multivariate Cox regression, with results expressed as hazard ratios, adjusted for patient and tumor characteristics, including a subgroup analysis of high-grade serous cancer. RESULTS: 5558 patients, treated between 2010 and 2019 were included (median age 65 IQR 57-71). Median second- and third line PFS and OS were proportionally higher with PFI prolongation. Other factors influencing PFS and OS were BRCA mutation, FIGO stage, chemotherapy and maintenance regimens, and PS. PBCT was more effective than single-agent chemotherapy, even with a PFI < 6 months (PFSn2: adjusted HR = 0.48 95 %IC [0.43;0.53], OSn2: HR = 0.51 95 %IC [0.46;0.57]). Use of PARP inhibitors (PARPi) in second line seems to reduce outcomes in the third line. Findings were consistent in the HGSC subgroup. CONCLUSION: PFI remains an important prognostic factor but should no longer be the sole consideration for treatment selection at relapse in EOC, particularly in HGSC. The potential impact of prior PARPi maintenance on subsequent PBCT warrants investigation in prospective trials.
引用
- Chator C, Chevrier M, Frenel JS, et al. Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database. Gynecol Oncol. 2025. PMID: 40779880. doi:10.1016/j.ygyno.2025.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。